Findings

What do systematic reviews say?

Ignored "BT": search terms need at least 3 characters.

707 questions · 750 findings · 36 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 56 · 7.5%GRADE not reported 200 · 26.7%Very low 142 · 18.9%Low 186 · 24.8%Moderate 132 · 17.6%High 34 · 4.5%

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Quality of life ‐ total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 115 participants
Very low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interpersonal Psychotherapy adapted for BPD (IPT‐BPD) vs clinical management (CM)

BPD total severityBPDSI‐IV1‐total score · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Interpersonal Psychotherapy adapted for BPD (IPT‐BPD) vs clinical management (CM)

AngerBPDSI‐IV1‐anger · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Interpersonal Psychotherapy adapted for BPD (IPT‐BPD) vs clinical management (CM)

Affective instabilityBPDSI‐IV1‐affective instability · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Interpersonal Psychotherapy adapted for BPD (IPT‐BPD) vs clinical management (CM)

Chronic feelings of emptinessBPDSI‐IV1‐emptiness · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Interpersonal Psychotherapy adapted for BPD (IPT‐BPD) vs clinical management (CM)

Impulsivity · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Interpersonal Psychotherapy adapted for BPD (IPT‐BPD) vs clinical management (CM)

ParasuicidalityBPDSI‐IV1‐parasuicidal behaviour · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low